Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.87 USD | +6.04% | +4.25% | +33.03% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+33.03% | 1.96B | C+ | ||
+55.70% | 55.7B | B- | ||
+41.08% | 39.91B | A | ||
-5.39% | 39.57B | B | ||
-5.56% | 28.16B | C | ||
+16.46% | 26.3B | B- | ||
-20.56% | 18.94B | B | ||
+33.03% | 12.17B | C+ | ||
+25.85% | 12.12B | B+ | ||
+2.72% | 12.12B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KYMR Stock
- Ratings Kymera Therapeutics, Inc.